Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) is projected to announce its Q4 2024 earnings results before the market opens on Tuesday, April 15th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). On average, analysts expect Greenwich LifeSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Greenwich LifeSciences Stock Up 1.2 %

Shares of Greenwich LifeSciences stock traded up $0.11 during trading hours on Friday, hitting $8.95. The company's stock had a trading volume of 71,770 shares, compared to its average volume of 43,836. The business has a fifty day moving average of $10.87 and a 200 day moving average of $12.38. Greenwich LifeSciences has a 1-year low of $8.06 and a 1-year high of $18.75. The company has a market capitalization of $117.65 million, a PE ratio of -11.19 and a beta of 1.76.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.

Insider Activity at Greenwich LifeSciences

In other news, CEO Snehal Patel acquired 5,500 shares of the stock in a transaction on Friday, April 4th. The stock was bought at an average price of $8.73 per share, with a total value of $48,015.00. Following the completion of the transaction, the chief executive officer now directly owns 5,558,002 shares of the company's stock, valued at $48,521,357.46. The trade was a 0.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 51.67% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Greenwich LifeSciences stock. Bank of America Corp DE raised its position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) by 22.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,262 shares of the company's stock after buying an additional 1,322 shares during the period. Bank of America Corp DE owned approximately 0.06% of Greenwich LifeSciences worth $82,000 at the end of the most recent quarter. Institutional investors own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.